EMPACT-MI: EMPAgliflozin for the Prevention of Chronic Heart Failure and MorTality After an Acute Myocardial Infarction.

Grants and Contracts Details

StatusActive
Effective start/end date4/21/2111/27/24

Funding

  • Boehringer Ingelheim Pharmaceuticals Incorporated (US): $24,725.00